Results 21 to 30 of about 207,050 (299)
Prostate-specific membrane antigen-based imaging [PDF]
Urologic Oncology: Seminars and Original Investigations, 2013 Prostate cancer (CaP) is the most common noncutaneous malignancy affecting men in North America. Despite significant efforts, conventional imaging of CaP does not contribute to patient management as much as imaging performed for other common cancers. Given the lack of specificity in conventional imaging techniques, one possible solution is to screen ...
Joseph R, Osborne +5 more
openaire +2 more sources
Cancer Reports, 2021 Background Dutasteride has been shown to increase expression of the prostate‐specific membrane antigen (PSMA) in prostate cancer cells in previous in vitro studies. This 5‐alpha‐reductase inhibitor is commonly used for the treatment of symptomatic benign
Benedikt Kranzbühler +7 more
doaj +1 more source
Advances in targeted Alpha therapy for prostate cancer [PDF]
, 2019 BACKGROUND: Amongst therapeutic radiopharmaceuticals, targeted alpha therapy (TαT) can deliver potent and local radiation selectively to cancer cells as well as the tumor microenvironment and thereby control cancer while minimizing toxicity.
De Vincentis, G +11 more
core +2 more sources
PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) AS DIAGNOSTIC BIOMARKER IN PROSTATE CANCER
Jurnal Urologi Indonesia, 2022 Objective: This study aimed to compare PSMA expression in both prostate cancer and benign prostate disease. Material & Methods: PSMA antigen expression was examined using polymerase chain reaction (PCR), twenty samples from each prostate cancer and ...
Lucky Frannata +3 more
doaj +1 more source
Components of cell-matrix linkage as potential new markers for prostate cancer [PDF]
, 2011 Prostate cancer is one of the most common tumor diseases worldwide. Often being non-aggressive, prostate tumors in these cases do not need immediate treatment.
Eble, Johannes Andreas, Navdaev, Alexey
core +2 more sources
Emerging treatments for recurrent prostate cancer [PDF]
, 2015 Despite radical treatment, many men with prostate cancer will develop recurrence of their disease. In an exciting era of new therapies for prostate cancer in general, we focus on how these will specifically benefit those men with recurrent disease.
Hanna, Catherine, Jones, Robert J.
core +1 more source
Xiehe Yixue Zazhi, 2022 Prostate cancer (PCa) is one of the most common malignancies and one major leading cause of mortality from cancers in old men. Due to its specific overexpression in PCa cells, the prostate specific membrane antigen (PSMA) has become an ideal molecular ...
LI Hui, YANG Zhi
doaj +1 more source
Loss of signal transducer and activator of transcription 1 is associated with prostate cancer recurrence [PDF]
, 2015 STAT1 loss has previously been implicated in cell line studies to modify prostate cancer cell growth and survival, however the clinical significance of this has not previously been established.
Edwards, Joanne +6 more
core +1 more source
Co-Catalytic Metallopeptidases as Pharmaceutical Targets [PDF]
, 2003 Understanding the reaction mechanism of co-catalytic metallopeptidases provides a starting point for the design and synthesis of new molecules that can be screened as potential pharmaceuticals. Many of the enzymes that contain co-catalytic metallo-active
Bzymek, Krzysztof P. +2 more
core +2 more sources
World Journal of Nuclear Medicine, 2020 Prostate-specific membrane antigen (PSMA) is a Type II transmembrane glycoprotein which is extremely overexpressed in prostate cancer epithelial cells. Recently, PSMA-targeted small molecule labeled with 68Ga and 99mTc allowed precise molecular imaging ...
Esmail Jafari +3 more
doaj +1 more source